Drugs / Adebrelimab
Trials 265 · started per year
today
1
3
2
9
4
8
21
103
66
48
20182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06735508 | Jan 2025 → Dec 2026 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06156267 | Jan 2024 → Apr 2026 overdue | pancreatic adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06685653 | ? → Nov 2026 expected | non-small cell lung carcinoma | Nanjing Tianyinshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT07063407 | Jul 2025 → Apr 2026 overdue | small cell lung carcinoma | Shanghai Hansoh Biomedical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07009457 | Jun 2025 → Sep 2027 expected | small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06963502 | May 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06902792 | Feb → Aug 2025 overdue | Langerhans cell histiocytosis | Second Affiliated Hospital of Wenzhou Medical University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06699576 | Dec 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06594874 | Oct 2024 → Oct 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06332170 | Apr 2024 → May 2026 overdue | neoplastic disease or syndrome | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06336707 | Apr 2024 → Apr 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06225921 | Dec 2023 → Jan 2025 | esophageal squamous cell carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06181032 | Dec 2023 → Feb 2029 expected | biliary tract cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT05198817 | Feb 2022 → Jan 2023 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05082545 | Nov 2021 → Jul 2023 | cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05048134 | Oct 2021 → Feb 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04979390 | Aug 2021 → Feb 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03995472 | Feb 2020 → Jan 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04041011 | Sep 2019 → Apr 2021 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03474289 | Mar 2018 → Jan 2019 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03133247 | Jun 2017 → Apr 2019 | cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1/231 trials | ||||||
| Phase 1/2 | NCT07806058 | Sep 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07736612 | Aug 2026 → Aug 2028 expected | malignant pancreatic neoplasm | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07615283 | May 2026 → May 2030 expected | mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07595172 | Apr 2026 → Aug 2028 expected | pancreatic ductal adenocarcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07392541 | Jan 2026 → Jan 2028 expected | biliary tract cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07296341 | Jan 2026 → Oct 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07229586 | Dec 2025 → Dec 2027 expected | neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07073534 | Jul 2025 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07059221 | Jul 2025 → Mar 2027 expected | head and neck squamous cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06840002 | Mar 2025 → Dec 2026 expected | ovarian cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06741020 | Mar 2025 → Jun 2026 overdue | hepatocellular carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06597513 | Dec 2024 → Dec 2025 overdue | small cell lung carcinoma | Zhou Chengzhi | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06592287 | Sep 2024 → Sep 2025 overdue | gastric cancer | Xianglin Yuan | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06776770 | Aug 2024 → Sep 2026 overdue | gastric cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06385678 | Jul 2024 → Dec 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06527898 | Jul 2024 → Jul 2026 overdue | small cell lung carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06474468 | Jun 2024 → Oct 2026 expected | esophageal cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06427239 | Jun 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06454448 | Jun 2024 → Jun 2025 overdue | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06439589 | Jun 2024 → Dec 2025 overdue | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06417554 | May 2024 → Jul 2027 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06373133 | May 2024 → Nov 2026 expected | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06332950 | Apr 2024 → Apr 2027 expected | small cell lung carcinoma | Baohui Han | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06222879 | Feb 2024 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06092268 | Oct 2023 → Dec 2025 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05924997 | Jul 2023 → Jun 2025 | hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05794477 | Apr 2023 → Jul 2025 | neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05765032 | Dec 2022 → Apr 2025 overdue | neoplasm | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05482568 | Sep 2022 → Dec 2026 expected | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04400188 | Jun 2020 → Jan 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2180 trials · 2 met primary | ||||||
| Phase 2 | NCT07811375 | Oct 2026 → Mar 2029 expected | cervical cancer | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07824882 | Sep 2026 → Mar 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07751341 | Sep 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07827053 | Sep 2026 → Sep 2029 expected | pancreatic ductal adenocarcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07865611 | Sep 2026 → Dec 2028 expected | urinary bladder carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07836543 | Sep 2026 → Dec 2029 expected | non-small cell lung carcinoma | Ming Chen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07684040 | Aug 2026 → Jul 2030 expected | liver cancer | Affiliated Hospital of Guangdong Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07704645 | Aug 2026 → Jun 2028 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07583550 | Jul 2026 → Oct 2027 expected | lung disorder | Jiangmen Central Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07567326 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Show all 180 trials opens the full record — a long page | ||||||
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07454720 | Mar 2026 → Nov 2032 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06879145 | Apr 2025 → Dec 2031 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06335355 | Mar 2024 → Oct 2028 expected | non-small cell lung carcinoma | Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 321 trials · 1 met primary | ||||||
| Phase 3 | NCT07822542 | Oct 2026 → May 2030 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07679360 | Sep 2026 → Dec 2030 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07691762 | Sep 2026 → Apr 2031 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07522151 | May 2026 → Dec 2029 expected | gastroesophageal cancer | Shanghai Shengdi Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07560358 | May 2026 → Dec 2029 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07464327 | Mar 2026 → Dec 2028 expected | non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07393542 | Feb 2026 → Sep 2027 expected | urothelial carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07229625 | Jan 2026 → Dec 2029 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07238569 | Dec 2025 → Dec 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07170995 | Oct 2025 → Dec 2030 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07168200 | Oct 2025 → Apr 2028 expected | cervical cancer | Shanghai Shengdi Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07111832 | Aug 2025 → Mar 2028 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07118527 | Aug 2025 → Oct 2030 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04516681 | Dec 2024 → Dec 2025 overdue | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06672133 | Dec 2024 → Jun 2029 expected | small cell lung carcinoma | Jinming Yu | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06618664 | Oct 2024 → Oct 2026 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05496166 | Aug 2023 → Aug 2027 expected | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04691063 | Jan 2021 → May 2025 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04316364 | Jul 2020 → Apr 2023 overdue | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03711305 | Dec 2018 → Oct 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT06417606 | May 2024 → Apr 2025 | intrahepatic cholangiocarcinoma | Zhiyong Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06192186 | Dec 2023 → Dec 2025 | gastric adenocarcinoma | Yang Jianjun, PhD | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07388095 | Feb 2026 → Feb 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06893887 | May 2025 → Dec 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
| — | NCT06853678 | Feb 2025 → Jul 2026 overdue | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT06480864 | Aug 2024 → Aug 2025 overdue | small cell lung carcinoma | Yunpeng Liu | Recruiting | No outcome recorded |
| — | NCT06613113 | Aug 2024 → Apr 2025 overdue | colorectal cancer | Ningbo Medical Center Lihuili Hospital | Recruiting | No outcome recorded |
| — | NCT06420908 | May 2024 → May 2026 | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT05132790 | Sep 2023 → Dec 2024 overdue | breast cancer | Shengjing Hospital | Active not recruiting | No outcome recorded |
| Comparator or background therapy37 trials | ||||||
| Phase 1 | NCT06350006 Background | May 2024 → Dec 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05942378 Background | Jul 2023 → Sep 2025 | cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT07239596 Background | Jan 2026 → Dec 2030 expected | renal cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07136142 Background | Sep 2025 → Feb 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07105592 Background | May 2025 → May 2027 expected | head and neck squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06754930 Background | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06639347 Background | Nov 2024 → May 2027 expected | urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06434103 Background | Oct 2024 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT06512051 Background | Jul 2024 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06474455 Background | Jul 2024 → Jun 2029 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06479473 Background | Jun 2024 → Mar 2025 overdue | small cell lung carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05416775 Background | Aug 2022 → Jun 2026 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05444088 Background | Aug 2022 → Jun 2026 | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT07863167 Comparator | Oct 2026 → Dec 2028 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07798947 Background | Sep 2026 → Dec 2028 expected | small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07682272 Background | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07241767 Background | Nov 2025 → Nov 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07131514 Background | Aug 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07137858 Comparator | Aug 2025 → Jun 2027 expected | oral cavity squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07071714 Background | Jul 2025 → Oct 2031 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06908668 Background | Mar 2025 → Sep 2028 expected | Her2-receptor negative breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06844474 Background | Mar 2025 → Dec 2026 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06739928 Background | Jan 2025 → Jun 2026 overdue | small cell lung carcinoma | Guangzhou Institute of Respiratory Disease | Recruiting | No outcome recorded |
| Phase 2 | NCT06610734 Background | Dec 2024 → Dec 2026 expected | small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06684158 Background | Nov 2024 → Mar 2027 expected | gastroesophageal junction adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06771609 Comparator | Sep 2024 → Sep 2028 expected | triple-negative breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06537505 Background | Aug 2024 → Apr 2027 expected | cancer | Beidahuang Industry Group General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06433609 Background | Aug 2024 → Mar 2027 expected | breast cancer | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06465563 Background | Jul 2024 → Dec 2026 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06247956 Background | Mar 2024 → Dec 2025 overdue | digestive system carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06165900 Background | Sep 2023 → Dec 2025 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06037655 Background | Sep 2023 → Mar 2026 overdue | biliary tract neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06791460 Background | Mar 2025 → Feb 2028 expected | ovarian carcinoma | Obstetrics & Gynecology Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06675214 Background | Jul 2024 → Jul 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06092957 Background | Oct 2023 → Oct 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 WCLC｜恒瑞医药十余项肺癌领域研究亮相国际舞台 hengrui.com ↗
在54例疗效可评估患者中，初步ORR 87.0%，疾病控制率（DCR）98.1%。 |
| 2026-09-14 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC hspharm.com ↗
HS-10370 plus adebrelimab and chemotherapy demonstrated promising anti-tumor activity as first-line therapy for KRAS G12C-mutated advanced NSCLC, with a confirmed ORR of 81.5%; median PFS was not reached, and the 12-month PFS rate was 78.7%. |
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ASCO口头报告｜恒瑞医药Nectin-4 ADC创新药SHR-A2102联合阿得贝利单抗围手术期治疗肌层浸润性膀胱癌研究结果重磅发布 hengrui.com ↗
北京时间5月30日，恒瑞医药自主研发的新型Nectin‑4 ADC创新药SHR‑A2102联合PD‑L1抑制剂阿得贝利单抗用于肌层浸润性膀胱癌（MIBC）围手术期治疗（SHR‑A2102‑303研究）II期阶段的初步研究结果重磅公布。 |
| 2026-04-22 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 AACR口头报告︱恒瑞医药阿得贝利单抗围术期治疗可切除II-IIIB期非小细胞肺癌III期研究结果重磅亮相 hengrui.com ↗
研究结果显示 1 ，该疗法在主要终点病理缓解率（MPR）和无事件生存期（EFS）上均取得了统计学显著且具有临床意义的改善，安全性良好。 |
| 2026-04-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AACR 2026 | HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS hspharm.com ↗
At AACR 2026, data from an expansion cohort of the phase 1 ARTEMIS-101 study evaluating risvutatug rezetecan plus adebrelimab in patients with previously treated nsq-NSCLC without AGAs were presented as an oral presentation. |
| 2026-04-01 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ELCC︱恒瑞医药4款创新药共7项肺癌研究亮相国际舞台 hengrui.com ↗
自2023年10月10日至2025年9月12日，共入组27例患者。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | Jiangsu HengRui Medicine Co., Ltd. | 2026 WCLC｜恒瑞医药十余项肺癌领域研究亮相国际舞台 hengrui.com ↗ |
| 2026-09-14 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC hspharm.com ↗ |
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ASCO口头报告｜恒瑞医药Nectin-4 ADC创新药SHR-A2102联合阿得贝利单抗围手术期治疗肌层浸润性膀胱癌研究结果重磅发布 hengrui.com ↗ |
| 2026-04-22 | Jiangsu HengRui Medicine Co., Ltd. | 2026 AACR口头报告︱恒瑞医药阿得贝利单抗围术期治疗可切除II-IIIB期非小细胞肺癌III期研究结果重磅亮相 hengrui.com ↗ |
| 2026-04-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | AACR 2026 | HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS hspharm.com ↗ |
| 2026-04-01 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ELCC︱恒瑞医药4款创新药共7项肺癌研究亮相国际舞台 hengrui.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 303 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adebrelimab | “This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without...” NCT06775275 ↗264“Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous...” NCT06417606 ↗ “a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until...” NCT06675214 ↗ “This prospective, single-arm, multicenter clinical study aims to preliminarily evaluate the efficacy and safety of Trastuzumab Rezetecan combined with Adebrelimab as...” NCT07624201 ↗ “Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease...” NCT06613113 ↗ “Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic...” NCT07170995 ↗ “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration).” NCT06908668 ↗ “We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC.” PMID 35576956 ↗ May 2022 “After 4 cycles of concurrent chemoradiotherapy, the non-progressing subjects will continue to receive adebrelimab (1200 mg, IV, Q3W) maintenance therapy.” NCT07559786 ↗ “Immunotherapy consolidation began at the third cycle of chemotherapy: Adebrelimab 1200mg q3w to 2 year or disease progression” NCT06527898 ↗ |
| Known as | ADE | “intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)” NCT06737913 ↗ |
| Known as | Adebrelimab Injection | “-Generic Name: Adebrelimab Injection -Trade name: Ariel -English name: Adebrelimab Injection” NCT06902792 ↗ |
| Known as | Ariel | “-Generic Name: Adebrelimab Injection -Trade name: Ariel -English name: Adebrelimab Injection” NCT06902792 ↗ |
| Known as | SHR-1316 | “The therapeutic aim of Adebrelimab (SHR-1316) is to inhibit tumor growth by specifically blocking the binding of PD-1 to PD-L1 and terminating the immunosuppressive signals...” NCT06405061 ↗48“A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative...” NCT07522151 ↗ “The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in...” NCT06178211 ↗ “Adebrelima(SHR-1316) is a recombinant humanized IgG4 antibody that binds efficiently and specifically to human and cynomolgus programmed cell death ligand 1 (PD-L1, CD274, or B7-H1)” NCT06375642 ↗ “Adebrelimab (SHR-1316) is a novel humanised IgG4 monoclonal antibody against PD-L1.” NCT07062328 ↗ “Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion” NCT06439589 ↗ “adebrelimab (SHR-1316), a novel anti-PD-L1 antibody” PMID 35576956 ↗ May 2022 “Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin” NCT06869213 ↗ “Drug: SHR-1316 given intravenously (IV).” NCT04041011 ↗ “SHR-1316（Adebrelimab Injection）” NCT06237257 ↗ |
| Action | Inhibit | “Anti-PD-L1 antibody” NCT04647357 ↗ |
| Modality | Monoclonal antibody | “SHR-1316 is a humanized IgG4 monoclonal antibody” NCT03133247 ↗ |
| Route | Intravenous | “SHR-1316 administrated intravenously(IV)” NCT03474289 ↗ |
| Target | CD274 | “binds efficiently and specifically to human and cynomolgus programmed cell death ligand 1 (PD-L1, CD274, or B7-H1)” NCT06375642 ↗ |